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Hypercapnia has been shown to impair alveolar ﬂuid reabsorption (AFR) by decreasing Na,K-ATPase
activity. Extracellular signal-regulated kinase pathway (ERK) is activated under conditions of cellu-
lar stress and has been known to regulate the Na,K-ATPase. Here, we show that hypercapnia leads to
ERK activation in a time-dependent manner in alveolar epithelial cells (AEC). Inhibition of ERK by
U0126 or siRNA prevented both the hypercapnia-induced Na,K-ATPase endocytosis and impairment
of AFR. Moreover, ERK inhibition prevented AMPK activation, a known modulator of hypercapnia-
induced Na,K-ATPase endocytosis. Accordingly, these data suggest that hypercapnia-induced
Na,K-ATPase endocytosis is dependent on ERK activation in AEC and that ERK plays an important
role in hypercapnia-induced impairment of AFR in rat lungs.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
For normal gas exchange to occur, it is essential to maintain the
lungs free of edema. The alveolar epithelium reabsorbs ﬂuid from
the alveolar spaces mostly via active Na+ transport where Na+ en-
ters the cells via apical sodium channels and it is extruded through
active transport driven by the basolateral Na,K-ATPase [1–4]. The
active Na+ transport across the alveolar epithelium creates an os-
motic gradient responsible for the clearance of lung edema [1–3].
We and others have reported that alveolar ﬂuid reabsorption
(AFR) is highly dependent on the Na,K-ATPase activity [1,5,6].
Hypercapnia (high levels of CO2 in the blood) occurs in patients
with chronic obstructive pulmonary disease [7,8], uncontrolled
asthma [9] and also in patients with lung injury who are mechan-
ically ventilated with the ‘‘permissive hypercapnia” strategy
[10,11]. We have previously shown that AFR is impaired during
hypercapnia and that cells exposed to high pCO2 have decreased
Na,K-ATPase activity due to a reduction in the Na,K-ATPase proteinchemical Societies. Published by E
kinase; AFR, alveolar ﬂuid
II alveolar epithelial
itical Care Medicine, Feinberg
uron, McGaw M300, Chicago,
Sznajder).abundance at the plasma membrane, suggesting hypercapnia-in-
duced Na,K-ATPase endocytosis [5,12,13].
Extracellular signal-regulated kinase 1 and 2 (ERK1 and ERK2)
are major members of the mitogen-activated protein kinase signal-
ing family and they regulate essential cellular processes [14,15].
For ERK 1/2 to be fully activated, dual phosphorylation of threonine
202 and tyrosine 204 of ERK1 and also threonine 183 and tyrosine
185 of ERK2 are required by an upstream kinase [15–18]. It has
been described that activation of ERK 1/2 plays a role in the traf-
ﬁcking of the Na,K-ATPase [19,20]. Here, we investigated whether
hypercapnia activates ERK 1/2 signaling pathways in alveolar epi-
thelial cells (AEC) and whether this activation regulates the Na,K-
ATPase and AFR as a measure of epithelial function.
2. Materials and methods
2.1. Reagents
All cell culture reagents were from Mediatech Inc., except for
the Ham’s F-12 which was from Sigma–Aldrich. 22Na+, 3H-manni-
tol, and c32P-ATP were from Perkin–Elmer. Ouabain was from
ICN Biomedical Inc. U0126 was from Promega. Na,K-ATPase
a1-subunit monoclonal antibody (clone 464.6) and AMPKa1-rabbit
polyclonal antibody were purchased from Upstate Biotechnology.
Phospho p44/42 MAPK and phospho-AMPKa rabbit monoclonal
antibodies, p44/42 MAPK mouse monoclonal antibody, AMPKalsevier B.V. All rights reserved.
Fig. 1. ERK 1/2 is activated in a time-dependent manner in AEC exposed to high
pCO2. ATII cells were exposed to 40 (black bars) or 120 (grey bars) mmHg pCO2 for
1–30 min. Phospho-ERK 1/2 and total amount of ERK 1/2 were measured by
Western blot analysis. Graph represents the phospho/total ERK 1/2 ratio. Values are
expressed as mean ± S.E.M., n = 4. Representative Western blots are shown.
**P < 0.01.
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linked, 10X Cell Lysis Buffer and SignalSilence p44/42 MAPK
(ERK1/2) siRNA were from Cell Signaling Technology. AMPKa1
siRNA was from Santa Cruz Biotechnology. Silencer Negative
Control #1 siRNA was from Ambion.
2.2. Animals
Pathogen-free adult male Sprague Dawley rats (300–325 g)
were used for isolated perfused rat lung model and male Sprague
Dawley rats (200–225 g) were used for alveolar epithelial type II
cell isolation (Harlan). Animals were provided with food and water
ad libitum, were maintained on a 12-h light/12-h dark cycle and
were handled according to NIH guidelines and the Northwestern
University Animal Care and Use Committee-approved experimen-
tal protocols.
2.3. Alveolar epithelial type II cell isolation and cell culture
Rat type II alveolar epithelial (ATII) cells were isolated as previ-
ously described [21,22]. The day of isolation and plating was des-
ignated cultured day 0. All experimental conditions were tested
in day 2 cells. Rat ATII, human A549 cells (ATCC #CCL-185) and
clones expressing the GFP-rat NKA-a1 (A549-GFP-a1) [23] were
grown in DMEM supplemented with 10% fetal bovine serum,
100 U/ml penicillin, 100 lg/ml streptomycin and 20 mM Hepes.
For the A549-GFP-a1 cells, 3 lM ouabain was added to the medium
to suppress the endogenous Na,K-ATPase a1-subunit. Cells were
incubated in a humidiﬁed atmosphere of 5% CO2/95% air at 37 C.
2.4. CO2 exposure
Solutions and exposure of cells in a C-Chamber in which the
atmosphere was controlled with a PRO-CO2 carbon dioxide con-
troller (Biospherix) was performed as previously described [13].
2.5. ERK 1/2 and AMPKa phosphorylation
For the detection of ERK 1/2 and AMPKa phosphorylation, after
exposure to hypercapnia for the appropriate times, cells were
washed in ice-cold phosphate-buffered saline and solubilized in ly-
sis buffer. The lysates were cleared by centrifugation for 10 min at
14,000g. Samples containing equal amounts (25–75 lg) of pro-
teins were resuspended in Laemmli sample buffer, boiled for
5 min, and subjected to Western blot analysis with speciﬁc anti-
bodies as described below.
2.6. Western blot
Protein concentration was quantiﬁed using Protein Assay Dye
(Bio-Rad). Proteins were then resolved in 10–12.5% polyacrylamide
gels (SDS–PAGE) as described previously [13].
2.7. Determination of Na,K-ATPase activity
After the treatments, Na-K-ATPase activity was determined by
[c-32P] ATP hydrolysis as previously described [5,24]. Na-K-ATPase
activity was calculated as the difference between test samples (to-
tal ATPase activity) and samples assayed in the same medium, but
devoid of Na+ and K+ and in the presence of 1 mM ouabain (oua-
bain-insensitive ATPase activity).
2.8. Biotinylation of cell surface proteins
After the treatments, cells were labeled for 20 min using 1 mg/
ml EZ-link NHS-SS-biotin (Pierce Biotechnology) in 10 mMTriethanolamine [pH 8], 2 mM CaCl2 150 mM NaCl as previously
described [5]. Proteins were analyzed by SDS–PAGE and Western
blot as described above.
2.9. Transient transfection
A549 or A549-GFP-a1 cells were grown on 35 mm plates at a
density of 2  105 cells per plate in DMEM with 10% fetal bovine
serum and 20 mM Hepes without antibiotics. Cells were transfec-
ted with SignalSilence p44/42 MAPK (ERK1/2) siRNA (10 picomol)
or AMPKa1 siRNA (100 picomol) by using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions. Hyper-
capnia exposure was performed after 48 h. A non-silencing siRNA
(10 picomol) was used as a negative control.
2.10. Isolated-perfused rat lung model
The isolated lung preparation has been described in detail pre-
viously [5,13].
2.11. Data analysis
Data are represented as means ± S.E.M. Multiple comparisons
were made using a one-way analysis of variance followed by a
multiple comparison test (Dunnett) when the F statistic indicated
signiﬁcance. Results were considered signiﬁcant when p < 0.05.3. Results
3.1. ERK 1/2 is activated in a time-dependent manner in AEC exposed
to hypercapnia
To investigate whether ERK 1/2 was activated during exposure
to hypercapnia, ATII cells were exposed for up to 30 min to
40 mmHg pCO2 (control) and 120 mmHg pCO2 (hypercapnia),
while buffering the pH to 7.4. As shown in Fig. 1, exposure of the
ATII cells to hypercapnia for as little as 1 minute stimulated ERK
1/2 phosphorylation.
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Na,K-ATPase downregulation
Previously, we have reported that AEC were sensitive to ele-
vated increasing levels of pCO2 [5,12,13]. We set out to determine
whether Na,K-ATPase activity and endocytosis were dependent on
ERK activation. ATII cells pre-treated with 10 lMU0126 for 30 min
were exposed to hypercapnia for 30 min and as shown in Fig. 2A
and B the ERK inhibitor U0126 prevented the hypercapnia-induced
decrease in Na,K-ATPase activity and protein abundance at the
plasma membrane. To further conﬁrm that the hypercapnia-in-
duced Na,K-ATPase endocytosis is dependent on ERK, A549-GFP-
a1 cells were transfected with ERK 1/2 siRNA (60% knockdown,
Fig. 2C). Forty-eight hours post-transfection cells were exposed
to hypercapnia for 30 min and as shown in Fig. 2C, the hypercap-
nia-induced downregulation of the Na, K-ATPase was prevented.
3.3. Inhibition of ERK 1/2 prevents the hypercapnia-induced
AMP-activated protein kinase (AMPK) activation
We have previously reported that AMPK is necessary for hyper-
capnia-induced Na,K-ATPase endocytosis [13]. To determine
whether ERK 1/2 is upstream of AMPK activation, we used speciﬁc
siRNA to knockdown ERK (60% knockdown) and studied AMPK
activation after exposure for 10 min to hypercapnia. As shown inFig. 2. Inhibition of ERK 1/2 prevents the hypercapnia-induced Na,K-ATPase downregul
then exposed to 40 (black bars) or 120 (grey bars) mmHg pCO2 for 30 min in the presence
(B) ATII cells treated as in (A) and Na,K-ATPase protein abundance at the plasma membra
blot against Na,K-ATPase a1-subunit. Total cell lysates are also shown. (C) A549-GFP-a1
exposed to 40 or 120 mmHg pCO2 for 30 min. The Na,K-ATPase protein abundance at the
total cell lysates for total ERK 1/2 and tubulin are shown. Graph represents the mean ±Fig. 3A, ERK knockdown completely abolished AMPK activation.
However, the opposite experiment (siRNA for AMPKa1, 80%
knockdown) did not prevent the hypercapnia-induced ERK activa-
tion (Fig. 3B).
3.4. ERK 1/2 regulates AFR in rat lungs exposed to hypercapnia
We have shown that high levels of pCO2 reduced AFR by 50%
[5,12,13]. To determine whether ERK 1/2 mediated the hypercap-
nia induced impairment of AFR, anesthetized Sprague Dawley rats
were pre-treated with 5 mg/kg U0126 or DMSO (I.V.) 30 minutes
prior to isolating the lungs and measuring AFR using our ex vivo
isolated-perfused rat lung model. As depicted in Fig. 4A and B,
pre-treatment with U0126 prevented the hypercapnia induced de-
crease in AFR, without affecting the epithelial barrier permeability.
4. Discussion
Hypercapnia (increased pCO2) occurs in patients with many
pulmonary diseases as a result of respiratory dysfunction. We
and others have reported that hypercapnia has deleterious effects
on the alveolar epithelium [5,12,13,25–27], independent of pH
and carbonic anhydrase [5,12]. Here, we provide ﬁrst evidence that
hypercapnia leads to a rapid ERK 1/2 phosphorylation, which has a
role in Na,K-ATPase endocytosis and decreased AFR.ation. (A) ATII cells were pre-treated with U0126 (10 lM) or DMSO for 30 min and
or absence of U0126. Na,K-ATPase activity was measured as [c-32P] ATP hydrolysis.
ne (PM) was determined by biotin-streptavidin pull down and subsequent Western
cells were transiently transfected with scrambled or ERK 1/2 siRNA and 48 h later
plasma membrane (PM) was determined as in (B). Representative Western blots of
S.E.M, n = 5. **P < 0.01.
Fig. 3. Inhibition of ERK1/2 prevents the hypercapnia-induced AMPK activation. (A) A549 cells transiently transfected with scrambled or ERK 1/2 siRNA and then exposed to
40 (black bars) or 120 (grey bars) mmHg pCO2 for 10 min. Phospho-AMPKa and total amount of AMPKa were measured by Western blot analysis. A representative Western
blot is shown for total ERK 1/2. (B) A549 cells transiently transfected with scrambled or AMPKa1 siRNA and then exposed to 40 or 120 mmHg pCO2 for 10 min. Phospho-ERK
1/2 and total amount of ERK 1/2 were measured by Western blot analysis. A representative Western blot of total cell lysates for total AMPKa1 is shown. Data represent the
mean ± S.E.M., n = 5. *P < 0.05, **P < 0.01.
Fig. 4. ERK 1/2 regulates AFR in rat lungs exposed to high pCO2. Anesthetized Sprague Dawley rats were pre-treated with 5 mg/kg U0126 or DMSO (I.V.) 30 min prior to the
isolated-perfused rat lung model. (A) Isolated rats lungs were perfused for 1 h with 40 mmHg pCO2 (black bars) or with approximately 60 mmHg pCO2 (grey bars) and AFR
was measured. (B) Passive ﬂuxes of 22Na+ (black bars) and 3H-mannitol (white bars) were measured. Bars represent the mean ± S.E.M, n = 5. **P < 0.01.
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as early as 1 min, peaking between 10 and 15 min and returning
almost to baseline by 30 min. There have been several reports
describing the role of ERK in the trafﬁcking of the Na,K-ATPase. It
has previously been shown that Na,K-ATPase was upregulated
via ERK-dependent pathways in AEC treated with either dopamine
or b-adrenergic agonists [28,29]; alternatively, a role for ERK regu-
lating the Na,K-ATPase endocytosis has also been shown in opos-
sum kidney cells [19]. We show that the hypercapnia-induced
Na,K-ATPase endocytosis was prevented by using the MEK inhibi-
tor, U0126 and siRNA against ERK 1/2 , allowing us to conclude that
ERK activation is necessary for Na,K-ATPase downregulation
during hypercapnia.
We have previously demonstrated the critical role that AMPK
plays in the hypercapnia-induced Na,K-ATPase endocytosis [13].
Surprisingly, we found that ERK is involved in the hypercapnia
activation of AMPK. This could indicate a role for ERK in theregulation of the upstream events that lead to AMPK phosphoryla-
tion which includes several kinases and phosphatases [30].
We show that when the MEK inhibitor U0126 is administered to
rats in vivo, it attenuated the hypercapnia-induced decrease in AFR
(see Fig. 4). U0126 has been used to study in vivo the role of ERK in
several models, such as the inﬂux of eosinophils in an animal mod-
el of asthma [31,32], and in the cerulein-induced pancreatitis in
rats [33]. Additionally, a recent study by Schuh and Pahl found in
a lipopolysaccharide-induced lung injury model that U0126 atten-
uated the effects of acute lung injury by reducing the inﬂammatory
cell inﬂux in the bronchoalveolar lavage of the mice [34]. Our study
suggests that inhibition of the ERK 1/2 signaling pathwaymay have
therapeutic potential for the treatment patients with hypercapnia.
In summary, we provide evidence that AEC exposed to
hypercapnia stimulated ERK 1/2 phosphorylation and caused Na,
K-ATPase endocytosis. Inhibition of ERK 1/2 prevented the hyper-
capnia-induced Na,K-ATPase downregulation. In addition, rats
L.C. Welch et al. / FEBS Letters 584 (2010) 3985–3989 3989pre-treated with ERK inhibitor U0126 protected the lungs from
hypercapnia-induced impairment of AFR and warrants further
studies to understand the molecular pathways involved in alveolar
epithelial dysfunction during hypercapnia.
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